24/7 Market News Snapshot 08 April, 2025 – CorMedix Inc. (NASDAQ:CRMD)

April 8, 2025

DENVER, Colo., 08 April, 2025 (www.247marketnews.com) – (NASDAQ:CRMD) are discussed in this article.
CorMedix Inc. has experienced a noteworthy upward shift in market performance, opening at $7.51 and currently trading at $7.37, marking an impressive 21.42% increase from the prior close of $6.07. This surge in share price highlights significant investor interest, underscored by a robust trading volume of 1.14 million shares, indicating heightened market activity and confidence. As a biopharmaceutical leader dedicated to developing therapeutic products for life-threatening conditions, CorMedix is effectively positioning itself within the sector.

In conjunction with this market momentum, CorMedix has reported strong preliminary results for the first quarter of 2025. The Company anticipates unaudited net revenue to reach approximately $39.0 million, accompanied by expected adjusted EBITDA exceeding $22.5 million, once final figures are confirmed. This growth reflects a substantial increase in order volume towards the end of March and enhanced inventory visibility amongst purchasing customers. Consequently, CorMedix has revised its sales guidance for the first half of 2025, projecting revenue to be between $62 million and $70 million.

Despite anticipated fluctuations in net sales for Q2 2025 attributed to shipment timing, CorMedix expects consistent patient utilization, alongside growth in patient enrollment and engagement. As part of its strategic initiatives, the Company plans to launch patient enrollment for its pivotal Phase 3 study of DefenCath in patients receiving Total Parenteral Nutrition (TPN) later this month. Should the FDA grant approval for this indication, CorMedix estimates the peak annual sales potential for DefenCath could reach between $150 million and $200 million, reflecting a significant addressable market of $500 million to $750 million.

Additionally, as of March 31, 2025, CorMedix maintains a solid financial footing, with approximately $77.5 million in cash and short-term investments, excluding restricted cash. The Company remains steadfast in its commitment to advancing innovative therapeutic solutions, paving the way for future growth and enhanced treatment possibilities for patients in critical need.

Related news for (CRMD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.